Tempus AI’s Post

October marks Breast Cancer Awareness Month, a global campaign aimed at increasing awareness of breast cancer, promoting early detection, prevention, diagnosis, treatment, and cure. At TRIO, we stand with the millions affected by breast cancer and remain committed to advancing research that drives better outcomes for patients. Five of the trials we conducted led to the approval of a drug or regimen that changed the breast cancer treatment landscape, evidencing how we can make strides toward a future without breast cancer. #BreastCancerAwareness #CancerResearch #OctoberBreastCancerAwareness2024

Menarini Stemline is a prime example of the use of precision medicine in the service of patients. They are pioneers in the approval of companion diagnostics (CDx) for targeted drugs in particular for breast cancer. Their product Elacestrant, as an oral SERD, has been approved for ESR1 mutated cases with a specific prior treatment profile, and Guardant360 CDx is the approved diagnostic test. **But here is the thing...** some patients whose test came back without a definitive result, and some patients who test negative for ESR1 mutations, ALSO stand to benefit from this oral SERD. Should it be up to the patients? Should they have a say on whether to give this medication a try? Here are a few important considerations: 1. Although driven by ESR1 mutated patients, PFS in ALL patients in the EMERALD trial showed improvement with Elacestrant without any sign of a negative impact on overall survival. 2. Oncologists routinely prescribe treatments for off-label use, taking into account their experience and their knowledge over the intricacies of their patient's case. 3. Only the patients themselves are in position to know how any benefit-risk ratio truly articulates within the specificity of their own lives 4. Wider use of both medications and testing will generate real-world data that will allow for ever more precise definitions of WHICH patients do stand to benefit. It is time we empower patients over their own testing data and health and treatment decision-making. We need to develop regulatory pipelines that will allow for this as it will unlock much needed development of precision medicine through real-world data, and at a scale that cannot be matched through piecemeal clinical trials. I think a good first step will be collecting data on the patient's point of view and experience with both companion diagnostic testing and the treatment decision-making process, in particular as they relate to all of the new approvals since 2020. Have you encountered any good data on this? Please leave in comments!

Recognizing the Importance of Early Detection: With one in eight women expected to develop breast cancer during their lifetime, per the CDC, early detection is the key to saving lives. When discovered early, and in the localized stage, the 5-year relative survival rate for breast cancer is 99%, per the American Cancer Society. The most important screening test for breast cancer is a mammogram, an X-ray of the breast that can detect breast cancer up to two years before the tumor can be felt by you or your doctor. “Patients should start anywhere between the ages of 40 and 50 and then get mammograms on an annual basis,” advises Dr. Audrey Gonzalez, MD, a family medicine physician with STHS Clinics. To schedule a mammogram, call #STHS Pre-Registration at (956) 388-2190. For more information on mammograms, check out our latest South Texas Health Minute on ValleyCentral.com. bit.ly/3VwvKzH

October is Breast Cancer Awareness Month- we want to highlight all of the ways that you can take charge of your breast health and prioritize early detection! Breast cancer is the second most common cancer in women (after lung cancer). Early detection of breast cancer vastly increases survival rates. Scheduling an annual mammogram after the age of 40 (or earlier, depending on your breast cancer risk factors) is one of the most important things women can do to ensure to take control of their health. https://lnkd.in/gtF3Ywn

Emotional stress is a significant factor that can lead to cancer metastasis, especially in breast cancer patients. This Breast Cancer Awareness Month, Mustafa Lab Technologies is committed to advancing our understanding of how mental health impacts cancer progression. Our latest study, supervised by Dr. Muhammad Mustafa, reveals the prognostic significance of emotional stress biomarkers in metastatic breast cancer. Support the cause, spread awareness, and help us work towards a future where emotional well-being is integral to cancer care. Read the full research paper: https://lnkd.in/djraZ726 Watch our video: https://lnkd.in/dmSSnfHS #MustafaLabTechnologies #BeKindBeTheCure #BreastCancerAwarenessMonth #MentalHealthMatters #CancerResearch

According to the National Breast Cancer Foundation, Inc., approximately 30% of all new cancer diagnoses in women will be breast cancer, and there are over 4 million breast cancer survivors in the U.S. Even with tremendous advancements in care, many breast cancer patients face challenging side effects from their treatment, including chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), which can negatively affect their care and impact their quality of life. Osmol is preparing to advance OSM-0205, our lead candidate, into the clinic by year's end for the treatment and prevention of CIPN and CICI – paving the way for optimal chemotherapy dosing and enhanced patient outcomes. Learn more about how patients can manage their chemotherapy side effects: https://bit.ly/3Y6Vx31 #BreastCancerAwarenessMonth #healthcare #biotechnology

As of now, the exact cause of breast cancer is still unknown. What is known are the risk factors that can increase the likelihood of developing breast cancer, namely: 1. Smoking and exposure to secondhand smoke 2. Poor diet (high in fat and low in fiber, containing preservatives/coloring agents) 3. First menstruation at age under 12 4. Menopause (cessation of menstruation) after age 50 5. Having the first child after age 35 6. Never breastfeeding 7. Having undergone surgery on the breast due to benign or malignant tumors 8. Family history of breast cancer Source : https://lnkd.in/gZ4F-wq6

🌸Early detection of breast cancer is vital for successful treatment and survival. 🌐The WHO highlights that many cancer cases are preventable, underscoring the importance of awareness and proactive health measures. ✨The dedication of healthcare professionals, researchers and advocates in advancing women's health is invaluable. ✨ Their efforts empower women to take charge of their health, ultimately reducing the burden of breast cancer and improving outcomes for all. #BreastCancerAwareness #EarlyPrevention

Today is #NationalMammographyDay! Mammograms are the best primary screening tool to find #breastcancer and can help save lives. 💗 Mammograms can detect breast cancer before any symptoms appear. Early detection increases the chances of successful treatment and survival. 💗 Mammograms help identify factors like breast density, which can impact your breast cancer risk. 💗Regular mammograms provide peace of mind! 💗 Detecting breast cancer at an early stage often requires less aggressive treatment.